Literature DB >> 21107093

Prostate cancer topography and patterns of lymph node metastasis.

Yuji Tokuda1, Lauren J Carlino, Anuradha Gopalan, Satish K Tickoo, Matthew G Kaag, Bertrand Guillonneau, James A Eastham, Howard I Scher, Peter T Scardino, Victor E Reuter, Samson W Fine.   

Abstract

Pelvic lymph node (LN) metastasis is a well-recognized route of prostate cancer spread. However, the relationship between topography and the pathologic features of primary prostatic cancers and patterns of pelvic LN metastasis has not been well studied. We reviewed original slides of radical prostatectomies and pelvic LN dissections from 125 patients with LN metastasis and recorded a total number of LN excised/laterality of positive LN, and localization, staging parameters, lymphovascular invasion, and volume of primary tumors. LN QUANTITY AND DISTRIBUTION: 14.6 (mean) and 13 (median) LNs were resected. Seventy-six (61%), 33 (26%), and 16 (13%) cases had 1, 2, and >2 positive LNs; whereas 58, 44, and 20 cases had LN metastasis on the right, left, and bilaterally. PATHOLOGIC FEATURES: Eighty-six percent (108 of 125) and 37% (46 of 125) of the cases showed extraprostatic extension and seminal vesicle invasion, whereas 64% cases showed lymphovascular invasion. Mean and median total tumor volumes were 6.39 and 3.92 cm, with ≥50% and ≥90% Gleason patterns 4/5 in 105 (84%) and 73 (58%) cases, respectively. CORRELATION WITH DOMINANT TUMOR LOCATION: Dominant lesions on radical prostatectomy were as follows: 50 right lobe, 44 left lobe, and 31 bilateral lobe tumors. Fifteen of 50 (30%) right lobe and 18 of 44 (41%) left lobe dominant tumors had LN metastasis on the contralateral side. Only 4% (5 of 125) of the cases were associated with anterior dominant tumors.
CONCLUSION: Thirty percent to 40% of LN metastases occurred contralateral to the dominant tumor. LN metastasis is overwhelmingly associated with high-grade, high-stage, and large volume disease. LN positivity is rarely associated with anterior dominant tumors.

Entities:  

Mesh:

Year:  2010        PMID: 21107093      PMCID: PMC3414911          DOI: 10.1097/PAS.0b013e3181fc679e

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  30 in total

1.  Lymphatic drainage of prostatic transition and peripheral zones visualized on a three-dimensional workstation.

Authors:  C Brössner; H Ringhofer; T Hernady; W Kuber; S Madersbacher; A Pycha
Journal:  Urology       Date:  2001-02       Impact factor: 2.649

Review 2.  Cancer volume and site of origin of adenocarcinoma in the prostate: relationship to local and distant spread.

Authors:  J E McNeal
Journal:  Hum Pathol       Date:  1992-03       Impact factor: 3.466

3.  Reliability of preoperative diagnostics and location of lymph node metastases in presumed unilateral prostate cancer.

Authors:  Dorothea Weckermann; Gabriele Holl; Robert Dorn; Theodor Wagner; Rolf Harzmann
Journal:  BJU Int       Date:  2007-05       Impact factor: 5.588

4.  Anterior prostate cancer: is it more difficult to diagnose?

Authors:  S R J Bott; M P A Young; M J Kellett; M C Parkinson
Journal:  BJU Int       Date:  2002-06       Impact factor: 5.588

5.  Standard versus limited pelvic lymph node dissection for prostate cancer in patients with a predicted probability of nodal metastasis greater than 1%.

Authors:  Karim Touijer; Farhang Rabbani; Javier Romero Otero; Fernando P Secin; James A Eastham; Peter T Scardino; Bertrand Guillonneau
Journal:  J Urol       Date:  2007-05-11       Impact factor: 7.450

6.  The mechanisms and prognostic significance of seminal vesicle involvement by prostate cancer.

Authors:  M Ohori; P T Scardino; S L Lapin; C Seale-Hawkins; J Link; T M Wheeler
Journal:  Am J Surg Pathol       Date:  1993-12       Impact factor: 6.394

7.  Correlation between side of palpable tumor and side of pelvic lymph node metastasis in clinically localized prostate cancer.

Authors:  S H Harrison; C Seale-Hawkins; C W Schum; J K Dunn; P T Scardino
Journal:  Cancer       Date:  1992-02-01       Impact factor: 6.860

8.  The value of computerized tomography scan and magnetic resonance imaging in staging prostatic carcinoma: comparison with the clinical and histological staging.

Authors:  E Mukamel; J Hannah; Z Barbaric; J B deKernion
Journal:  J Urol       Date:  1986-12       Impact factor: 7.450

9.  Can digital rectal examination or transrectal ultrasonography biopsy findings predict the side of nodal metastasis in prostate cancer?

Authors:  Philippe E Spiess; Joseph E Busby; Jennifer J Jordan; Jordan R Steinberg; Roland L Bassett; Raj Davuluri; Kristina Burt; Patricia Troncoso; Andrew K Lee; Sarah H Taylor; Louis L Pisters
Journal:  Urol Oncol       Date:  2007-10-18       Impact factor: 3.498

10.  Anterior-predominant prostatic tumors: zone of origin and pathologic outcomes at radical prostatectomy.

Authors:  Hikmat A Al-Ahmadie; Satish K Tickoo; Semra Olgac; Anuradha Gopalan; Peter T Scardino; Victor E Reuter; Samson W Fine
Journal:  Am J Surg Pathol       Date:  2008-02       Impact factor: 6.394

View more
  11 in total

Review 1.  Sentinel node evaluation in prostate cancer.

Authors:  Ramkishen Narayanan; Timothy G Wilson
Journal:  Clin Exp Metastasis       Date:  2018-09-05       Impact factor: 5.150

2.  [68Ga-PSMA-I&T PET/CT for assessment of tumor burden in primary lesions of treatmentnaïve prostate cancer].

Authors:  Y Xie; C Li; L Zhang; S Zang; F Yu; S Wang; F Wang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-08-20

3.  Pathological features of lymph node metastasis for predicting biochemical recurrence after radical prostatectomy for prostate cancer.

Authors:  Sigrid V Carlsson; Laura J Tafe; Daher C Chade; Daniel D Sjoberg; Niccolo Passoni; Shahrokh F Shariat; James Eastham; Peter T Scardino; Samson W Fine; Karim A Touijer
Journal:  J Urol       Date:  2012-10-22       Impact factor: 7.450

4.  68Ga-PSMA-617 PET/CT: a promising new technique for predicting risk stratification and metastatic risk of prostate cancer patients.

Authors:  Chen Liu; Teli Liu; Ning Zhang; Yiqiang Liu; Nan Li; Peng Du; Yong Yang; Ming Liu; Kan Gong; Xing Yang; Hua Zhu; Kun Yan; Zhi Yang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-05-02       Impact factor: 9.236

5.  A Clinical and Experimental Comparison of Time of Flight PET/MRI and PET/CT Systems.

Authors:  Daniela E Oprea-Lager; Maqsood Yaqub; Indra C Pieters; Rinze Reinhard; Reindert J A van Moorselaar; Alfons J M van den Eertwegh; Otto S Hoekstra; Adriaan A Lammertsma; Ronald Boellaard
Journal:  Mol Imaging Biol       Date:  2015-10       Impact factor: 3.488

6.  Can pelvic node dissection at radical prostatectomy influence the nodal recurrence at salvage lymphadenectomy for prostate cancer?

Authors:  Arjun Sivaraman; Nicole Benfante; Karim Touijer; Jonathan Coleman; Peter Scardino; Vincent Laudone; James Eastham
Journal:  Investig Clin Urol       Date:  2018-02-22

7.  Stabilization of ADAM9 by N-α-acetyltransferase 10 protein contributes to promoting progression of androgen-independent prostate cancer.

Authors:  Yung-Wei Lin; Yu-Ching Wen; Chih-Ying Chu; Min-Che Tung; Yi-Chieh Yang; Kuo-Tai Hua; Ke-Fan Pan; Michael Hsiao; Wei-Jiunn Lee; Ming-Hsien Chien
Journal:  Cell Death Dis       Date:  2020-07-27       Impact factor: 8.469

8.  Pixel Prostate Software as a Reliable Tool in Depicting Spatial Distribution and Determination of the Prostate Cancer Volume.

Authors:  Damir Aganovic; Benjamin Kulovac; Svjetlana Radović; Nurija Bilalović; Senad Bajramović; Amel Kešmer
Journal:  Acta Inform Med       Date:  2019-06

9.  Dual-phase PET-CT to differentiate [18F]Fluoromethylcholine uptake in reactive and malignant lymph nodes in patients with prostate cancer.

Authors:  Daniela E Oprea-Lager; Andrew D Vincent; Reindert J A van Moorselaar; Winald R Gerritsen; Alfons J M van den Eertwegh; Jonas Eriksson; Ronald Boellaard; Otto S Hoekstra
Journal:  PLoS One       Date:  2012-10-31       Impact factor: 3.240

Review 10.  Diffusion-weighted imaging (DWI) in lymph node staging for prostate cancer.

Authors:  Iztok Caglic; Tristan Barrett
Journal:  Transl Androl Urol       Date:  2018-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.